Biotech Firm Attovia Therapeutics Surges Nearly 29% in Nasdaq Debut

Stock News

Aug 06

Wednesday marked the first trading day for biotech company Attovia Therapeutics (ATTO.US) on the Nasdaq, with shares closing up 28.82% at $21.90. The IPO was priced at $17 per share. Founded in 2022, the company's core technology is the "ATTOBODY" platform, a biparatopic nanobody-based biotech platform exclusively licensed from Alamar Biosciences (ALMR.US). This platform enables the development of multispecific antibody therapies targeting complex immune targets.

Currently, Attovia has three drug candidates in development. The most advanced asset is ATTO-1310, which has completed Phase I clinical trial dosing in healthy volunteers and patients with chronic pruritus and atopic dermatitis. ATTO-2306 is a bispecific antibody targeting IL-13 and IL-31, aiming for broader efficacy coverage in atopic dermatitis. ATTO-1091 is a trispecific antibody targeting three hot immune targets—TL1A, IL-23, and integrin α4β7—focusing on the large inflammatory bowel disease market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1156871449"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156871449\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156871449?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 06:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156871449","market":"sg","top_or_hot":-1,"title":"Biotech Firm Attovia Therapeutics Surges Nearly 29% in Nasdaq Debut","media":"Stock News","content":"<p>Wednesday marked the first trading day for biotech company <b>Attovia Therapeutics (ATTO.US)</b> on the Nasdaq, with shares closing up 28.82% at $21.90. The IPO was priced at $17 per share. Founded in 2022, the company's core technology is the \"ATTOBODY\" platform, a biparatopic nanobody-based biotech platform exclusively licensed from <b>Alamar Biosciences (ALMR.US)</b>. This platform enables the development of multispecific antibody therapies targeting complex immune targets.<br><br>Currently, <b>Attovia</b> has three drug candidates in development. The most advanced asset is <b>ATTO-1310</b>, which has completed Phase I clinical trial dosing in healthy volunteers and patients with chronic pruritus and atopic dermatitis. <b>ATTO-2306</b> is a bispecific antibody targeting IL-13 and IL-31, aiming for broader efficacy coverage in atopic dermatitis. <b>ATTO-1091</b> is a trispecific antibody targeting three hot immune targets—TL1A, IL-23, and integrin α4β7—focusing on the large inflammatory bowel disease market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Firm Attovia Therapeutics Surges Nearly 29% in Nasdaq Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Firm Attovia Therapeutics Surges Nearly 29% in Nasdaq Debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-06 06:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Wednesday marked the first trading day for biotech company <b>Attovia Therapeutics (ATTO.US)</b> on the Nasdaq, with shares closing up 28.82% at $21.90. The IPO was priced at $17 per share. Founded in 2022, the company's core technology is the \"ATTOBODY\" platform, a biparatopic nanobody-based biotech platform exclusively licensed from <b>Alamar Biosciences (ALMR.US)</b>. This platform enables the development of multispecific antibody therapies targeting complex immune targets.<br><br>Currently, <b>Attovia</b> has three drug candidates in development. The most advanced asset is <b>ATTO-1310</b>, which has completed Phase I clinical trial dosing in healthy volunteers and patients with chronic pruritus and atopic dermatitis. <b>ATTO-2306</b> is a bispecific antibody targeting IL-13 and IL-31, aiming for broader efficacy coverage in atopic dermatitis. <b>ATTO-1091</b> is a trispecific antibody targeting three hot immune targets—TL1A, IL-23, and integrin α4β7—focusing on the large inflammatory bowel disease market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATTO","symbol_name":"Attovia Therapeutics","start_time":0,"source_url":"","article_id":"1156871449","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156871449","pubTimestamp":1785968953,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Wednesday marked the first trading day for biotech company Attovia Therapeutics (ATTO.US) on the Nasdaq, with shares closing up 28.82% at $21.90. The IPO was priced at $17 per share. Founded in 2022,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATTO":"Attovia Therapeutics","BK4143":"办公服务与用品","BK4226":"数据处理及外包服务"},"translate_title":"生物技术公司 Attovia Therapeutics 在纳斯达克首次亮相股价飙升近 29%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATTO":1},"content_text":"Wednesday marked the first trading day for biotech company Attovia Therapeutics (ATTO.US) on the Nasdaq, with shares closing up 28.82% at $21.90. The IPO was priced at $17 per share. Founded in 2022, the company's core technology is the \"ATTOBODY\" platform, a biparatopic nanobody-based biotech platform exclusively licensed from Alamar Biosciences (ALMR.US). This platform enables the development of multispecific antibody therapies targeting complex immune targets.Currently, Attovia has three drug candidates in development. The most advanced asset is ATTO-1310, which has completed Phase I clinical trial dosing in healthy volunteers and patients with chronic pruritus and atopic dermatitis. ATTO-2306 is a bispecific antibody targeting IL-13 and IL-31, aiming for broader efficacy coverage in atopic dermatitis. ATTO-1091 is a trispecific antibody targeting three hot immune targets—TL1A, IL-23, and integrin α4β7—focusing on the large inflammatory bowel disease market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}